MSL Leaders



	Search:

MS Practice Profiles: Cognitive Dysfunction in MS

Sponsored by the Postgraduate Institute for Medicine

Release date: September 12, 2007
Expiration date: September 12, 2008
Estimated time to complete activity: 15 minutes

This educational program is supported through educational grants from Biogen IDEC and Elan Pharmaceuticals Inc.

Several disturbances in thought processes occur in persons with MS, including slowed cognition, impaired concentration and memory, loss of complex language, and impaired problem solving and decision-making capacity. Early diagnosis of cognitive problems also enables clinicians to refer early for rehabilitation and appropriate therapies. This program includes available screening tools and a review of the use of disease-modifying agents.

Learning objectives:
Upon completion of this activity, the participant will be able to:

Cite the nature of cognitive dysfunction affecting some patients with multiple sclerosis.
Identify neuropsychological screening tests used to assess cognitive impairment in patients with multiple sclerosis.
Name a treatment that has been found in a study to provide significant improvement on memory testing for patients with patients with cognitive impairment.

Program Co-Chairs:
Robert J. Fox, MD
Staff Neurologist
The Cleveland Clinic
Cleveland, Ohio

Nilay Shah, MD Director, Neurology Division
Riverfront Medical Associates
Edgewater, NJ

Author:
Jeffrey A. Wilken, PhD
Assistant Professor of Neurology
Georgetown University Medical Center
Washington, DC

Instructions for Credit
Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Healthology, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

California Board of Registered Nursing
Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 0.25 contact hours.

Fee Information
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities.
All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations.
PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

The following faculty reported a real or apparent conflict of interest:
Robert J. Fox, MD (Co-Chair) Type of financial relationship: Consultant Grants/Research Support and Honorarium for: Genentech, Merck, Biogen IDEC, Questcor and TevaNeuroscience
Nilay Shah, MD (Co-Chair): Has no relevant information to disclose.
Jeffrey A. Wilken, PhD (Author): Type of financial relationship: Speaker’s Bureau: Biogen; Consultant Grants/Research Support: Biogen, Schering Plough, and Cognition Pharmaceuticals

Click here for the complete CME information


	Search: